Evommune (EVMN) Fundamentals 2026 — Revenue Analysis | SniperIQ
Evommune (EVMN) is a US-listed Healthcare company in Biotechnology with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Evommune's market cap?
Evommune (EVMN) has a market capitalization of approximately
What is Evommune's P/E ratio?
Evommune's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Evommune?
Evommune runs a net profit margin of -759.9%, a gross margin of 92.8%, and an operating margin of -899.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Evommune generate?
Evommune reported revenue of
Does Evommune pay a dividend?
Evommune does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Evommune financially healthy?
Evommune carries a debt-to-equity ratio of 0.03x and a current ratio of 20.36x, with a market beta of 0.86. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Evommune a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Evommune (EVMN) the key facts are: market cap
Track Evommune's full fundamentals live
Get Evommune's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.